Literature DB >> 26612877

Prevalence of hypertension subtypes in 2011 and the trends from 1991 to 2011 among Chinese adults.

Su-Fen Qi1, Bing Zhang2, Hui-Jun Wang2, Jing Yan3, Ying-Jun Mi1, Dian-Wu Liu1, Qing-Bao Tian1.   

Abstract

BACKGROUND: This study aims to estimate the current prevalence and trends of hypertension subtypes among Chinese adults from 1991 to 2011.
METHODS: We analysed the measurements of systolic and diastolic blood pressure among adults aged ≥18 years from the China Health and Nutrition Survey (CHNS) 1991-2011. The prevalence was age-adjusted to the 2010 census of Chinese adults.
RESULTS: The adjusted prevalence in 2011 was 20.9% (95% CI 20.2% to 21.6%) of hypertension, 3.30% (95% CI 2.99% to 3.62%) of isolated systolic hypertension, 4.44% (95% CI 4.08% to 4.80%) of isolated diastolic hypertension, 4.11% (95% CI 3.76% to 4.46%) of systolic-diastolic hypertension and 9.01% (95% CI 8.51% to 9.51%) of current use of antihypertensive medication, respectively. From 1991 to 2011, the prevalence increased from 15.6% to 20.9% for hypertension (p<0.001) and from 3.04% to 3.30% for isolated systolic hypertension (p<0.001). However, the prevalence decreased from 4.77% to 4.44% for isolated diastolic hypertension (p=0.023) and from 5.27% to 4.11% for systolic-diastolic hypertension (p<0.001). Consistent with these findings, the percentage of current use of antihypertensive medication increased from 2.55% to 9.01%, which accounted for approximately 43.1% of the total number of cases in 2011. Importantly, only 36.9% (equivalent to 17.5% of the total number of hypertensive people) of cases of current use of antihypertensive medication were adequately controlled.
CONCLUSIONS: Both the prevalence of hypertension and the percentage of current use of antihypertensive medication significantly increased from 1991 to 2011. Currently, about one-fifth of Chinese adults are hypertensive; however, only 17.5% of hypertension is controlled. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  EPIDEMIOLOGY; HYPERTENSION; OBESITY

Mesh:

Year:  2015        PMID: 26612877      PMCID: PMC6550331          DOI: 10.1136/jech-2015-206492

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  17 in total

1.  The comparison of percent body fat estimated by different anthropometrics to predict the incidence of hypertension.

Authors:  Yongjie Chen; Xuan Liang; Senshuang Zheng; Yuan Wang; Wenli Lu
Journal:  J Hum Hypertens       Date:  2019-09-02       Impact factor: 3.012

2.  Comparing the measurement properties of the EQ-5D-5L and the EQ-5D-3L in hypertensive patients living in rural China.

Authors:  Jie Jiang; Yanming Hong; Tiantian Zhang; Zhihao Yang; Tengfei Lin; Zhuoru Liang; Peiyao Lu; Lishun Liu; Binyan Wang; Yongmei Xu; Nan Luo
Journal:  Qual Life Res       Date:  2021-04-05       Impact factor: 4.147

Review 3.  Is Isolated Diastolic Hypertension an Important Phenotype?

Authors:  Cesar A Romero; Aldo H Tabares; Marcelo Orias
Journal:  Curr Cardiol Rep       Date:  2021-10-16       Impact factor: 2.931

4.  Early intervention of long-acting nifedipine GITS reduces brachial-ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study.

Authors:  Jidong Zhang; Yan Wang; Haijuan Hu; Xiaohong Yang; Zejun Tian; Demin Liu; Guoqiang Gu; Hongmei Zheng; Ruiqin Xie; Wei Cui
Journal:  Drug Des Devel Ther       Date:  2016-10-18       Impact factor: 4.162

5.  The Current Situation of Hypertension among Rural Minimal Assurance Family Participants in Liaoning (China): A Cross-Sectional Study.

Authors:  Yintao Chen; Shasha Yu; Shuang Chen; Xiaofan Guo; Yuan Li; Zhao Li; Yingxian Sun
Journal:  Int J Environ Res Public Health       Date:  2016-12-02       Impact factor: 3.390

6.  Transcutaneous electrical acupoint stimulation for stage 1 hypertension: protocol for a randomized controlled pilot trial.

Authors:  Zhong-Xue Tian; Cun-Zhi Liu; You-Sheng Qi; Jian-Feng Tu; Ying Lin; Yu Wang; Jing-Wen Yang; Guang-Xia Shi; Jun-Hong Liu; Li-Qiong Wang
Journal:  Trials       Date:  2020-06-22       Impact factor: 2.279

7.  Health-Related Quality of Life of Hypertension Patients: A Population-Based Cross-Sectional Study in Chongqing, China.

Authors:  Meng Xiao; Fan Zhang; Nanzi Xiao; Xiaoqing Bu; Xiaojun Tang; Qian Long
Journal:  Int J Environ Res Public Health       Date:  2019-07-03       Impact factor: 3.390

8.  Hypertension prevalence alteration in 92 815 nurses based on the new standard by 2017 ACC/AHA hypertension guideline: observational cross-sectional study from China.

Authors:  Bin Zhao; Jing Li; Jie Liu; Yuming Hao; Yanjie Zhen; Di Feng; Menghui Xu; Ximin Chen; Xiulan Yang; Aifang Zuo; Rufu Jia; Ruiqin Zhang; Ailing Fan; Yun Wang; Meijin Yuan; Li Tong; Shuling Chen; Jing Cui; Meizhu Zhao; Wei Cui
Journal:  BMJ Open       Date:  2019-08-30       Impact factor: 2.692

9.  Associations between serum uric acid and the incidence of hypertension: a Chinese senior dynamic cohort study.

Authors:  Fengjiang Wei; Ning Sun; Chunyou Cai; Shuzhi Feng; Jianli Tian; Wentao Shi; Weili Xu; Yaogang Wang; Xilin Yang; Wei-Dong Li
Journal:  J Transl Med       Date:  2016-04-30       Impact factor: 5.531

10.  Twenty-year time trends in hypertension prevalence in Yi people of China: three successive cross-sectional studies, 1996-2015.

Authors:  Jia Zhang; Shaoping Wan; Biao Zhang; Fen Dong; Li Pan; Wuli Yihuo; Haiying Gong; Fang Yang; Guodong Xu; Zheng Li; Guoju Li; Yanlong Li; Xiaoyang Wang; Guangliang Shan
Journal:  BMJ Open       Date:  2018-10-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.